In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nanosphere faces "period in purgatory" after "long-overdue" CEO change

This article was originally published in Clinica

Executive Summary

Molecular diagnostics company Nanosphere has appointed Michael McGarrity CEO, replacing William Moffitt, in a personnel overhaul that has also seen four board members resign. The changes were "necessary and long overdue" after a "track record littered with numerous operational disappointments", according to Jefferies analyst Jon Wood, who added that the "changes may very well be the perfect antidote to perennial under-performance". Even so, the firm's share "may see a period in purgatory" as "new leadership faces an uphill battle to re-gain investor trust", wrote the analyst. Nanosphere's shares are currently trading at around $2.64 on Nasdaq.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts